Trial · NCT07602140
TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.
NCT07602140, Phase 2, Not yet recruiting, Shandong Provincial Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study. Trials, record NCT07602140. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07602140
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.
- NCT number
- NCT07602140
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Shandong Provincial Hospital
- Conditions
- Gastric Cancer With Liver Metastases
- Interventions
- TACE combined with thermal ablation, Targeted Therapy, Immunotherapy, Chemotherapy
- First posted
- 2026-05-22
- Last updated
- 2026-05-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | Approximately 1 month after imaging examination | The proportion of subjects who achieve complete response (CR) and partial response (PR) among the total subjects. |
| Secondary | Progression-Free Survival（PFS） | Approximately 1 day after disease progression or death from any cause in cancer patients. | The time from treatment initiation to disease progression or death from any cause in cancer patients. |
| Secondary | Disease Control Rate（DCR） | Approximately 1 month after imaging examinatio | The proportion of patients with tumor shrinkage or stabilization maintained for a certain duration, including those with complete response (CR), partial response (PR), and stable disease (SD). |
| Secondary | Overall Survival (OS) | Approximately 2 years after last participant enrollment | The time from initial treatment to death from any cause |
| Secondary | Adverse Event (AE) | Approximately 2 month after any treatment | Type, incidence, grading (based on NCI-CTCAE v5.0 criteria), and duration of adverse event |
| Secondary | R0 resection rate | According to the postoperative pathological results, it is generally 2 weeks after surgery | Through postoperative pathological examination, it was confirmed that all surgical margins (including peripheral margins, deep margins, circumferential margins, etc.) of the excised specimen did not show any residual tumor cells under the microscope, indicating a negative margin and complete resection of the tumor without visible tumor remnants under the naked eye or microscope. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07602140
GET https://conductscience.org/api/trials/v1/NCT07602140/registered